New data presented at the ESMO World Congress on Gastrointestinal Cancer 2019 suggest the combination of encorafenib, binimetinib and cetuximab (ENCO+BINI+CETUX) improves survival in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) compared with the standard of care chemotherapy
The findings come from the international, randomised, open-label, three-arm, phase 3 BEACON CRC study in which 665 patients with BRAF V600E-mutant CRC who had progressed after 1-2 prior regimens in the metastatic setting were randomised to receive ENCO+BINI+CETUX, ENCO+CETUX or the investigator’s choice of irinotecan or folinic acid, fluorouracil and irinotecan (FOLFIRI) and cetuximab.
The data revealed median overall survival (OS) of nine months with ENCO+BINI+CETUX compared to 5.4 months with standard therapy (hazard ratio [HR] 0.52; 95% CI 0.39-0.7; P<.0001 median os was months with enco compared to standard therapy ci>
Objective response rate (ORR) was 26 per cent with ENCO+BINI+CETUX compared to 2 per cent for standard therapy (P<.0001>
BRAF V600E targeted treatment was associated with grade ≥3 adverse events in 58 per cent of patients on triplet treatment, 50 per cent of those in the doublet group and 61 per cent of those in the standard therapy group.